Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients
 with partial-onset seizures in routine clinical practice setting receiving adjunctive
 Vimpat®. The observed population will be only patients with one baseline antiepileptic drug.
 Seizure control and tolerability data will be evaluated.
Inclusion Criteria:

 -  The patient's treatment must be in accordance with the local marketing authorization
 (MA) for Vimpat®

 -  The decision to prescribe Vimpat® has to be made by the physician before and
 independently of his/her decision to include the patient in the study

 -  The Vimpat® treatment should have been started not longer than 2 weeks before study
 inclusion of the patient

 -  The patient must have a diagnosis of Epilepsy with Partial-Onset Seizures

 -  Based on the physician's clinical judgment, the patient's seizure activity is not
 controlled sufficiently on a current monotherapy and it is in the patient's best
 interest to be prescribed adjunctive Vimpat®

 Exclusion Criteria:

 In accordance with the Summary of Product Characteristics (SmPC)